![System.Func`1[System.String]](/siteassets/images/z-mckesson-logosicons/health-systems2.png)
Hear from our experts on how smarter scheduling and technology strengthen patient experience in health system infusion centers.
How Biosimilars Differ from Biologics in Cost and Benefits
Increased affordability of biosimilars may have an impact on healthcare systems.
By
Date
August 01, 2022
By: McKesson Medical Surgical Editorial Team
Read time: 1 minute
An overview of biosimilars and how they compare to biologics
Health systems and clinics considering the adoption of biosimilars for treatment should understand and consider how they compare to biologics. Biosimilar products are therapies that have the same therapeutic value and potency as their biologic counterparts, the use of biosimilar drugs may save money for both patients and providers. Increased affordability of the biosimilars may also have a meaningful impact on the healthcare system.
To learn more, read What are biosimilars? How biosimilars differ from biologics in cost & benefits.
Subscribe Now
To learn how McKesson can help health systems achieve more, sign up to have the Prescribed Perspectives newsletter delivered directly to your inbox.
Related Stories
The most downloaded content by health system pharmacy leaders in December 2025.
This interactive checklist guides you through 10 critical questions that can help uncover next steps for your health system’s specialty pharmacy strategy.
Get to know one of our McKesson Health Systems pharmacy experts and industry-leading voices, Rafael Saenz.
Hospital leaders discuss ambulatory pharmacy strategies, 340B considerations, and value-based care optimization at McKesson's Becker's Roundtable session.
This interactive checklist guides you through 5 critical questions that can help uncover next steps for your health system’s infusion service line.
The most downloaded content by health system pharmacy leaders in November 2025.
Take a look at the industry insights, experience, and expertise you’ll have access to at this year’s ASHP Midyear.
Do you know where your health system infusion patients are going – and, more importantly, why?
Answering these questions can help differentiate transactional vendor relationships from strategic partnerships that add value.